The Medical Letter on Drugs and Therapeutics
Radium-223 (Xofigo) for Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Radium Ra 223 dichloride (Xofigo – Bayer), a radiotherapeutic drug, has been approved by the FDA for intravenous treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.

MECHANISM OF ACTION — Radium-223 is a calcium mimetic that targets and binds to areas of high bone turnover, such as sites of bone metastases, and releases high-energy, short-range (<100 micrometers) alpha particles to produce a localized cytotoxic effect.

STANDARD TREATMENT — Docetaxel-based chemotherapy, abiraterone acetate (Zytiga), cabazitaxel (Jevtana), enzalutamide (Xtandi), and the autologous immunotherapy agent sipuleucel-T (Provenge) have each been shown to prolong survival in men with metastatic castration-resistant prostate cancer.1-3 Although not ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Radium-223 (Xofigo) for Prostate Cancer
Article code: 1426c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian